Literatur
-
1
Karvonen M, Viik-Kajander M, Moltchanova E et al.
Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group.
Diabetes Care.
2000;
23
1516-1526
-
2
Patterson C C, Dahlquist G G, Gyürüs E et al.
Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–2020: a multicentre prospective registration study.
Lancet.
2009;
373
2027-2033
-
3
Ehehalt S, Blumenstock G, Willasch A M et al.
Continuous rise in incidence of childhood Type 1 diabetes in Germany.
Diabet Med.
2008;
25
755-757
-
4
Dabela D, Bell R A Writing Group for the SEARCH for Diabetes in Youth Study Group et al.
Incidence of diabetes in youth in the United States.
JAMA.
2007;
297
2716-2724
-
5
Achenbach P, Bonifacio E, Koczwara K et al.
Natural history of type 1 diabetes.
Diabetes.
2005;
54
S25-S31
-
6
Ziegler A G, Hummel M, Schenker M et al.
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.
Diabetes.
1999;
48
460-468
-
7
Hummel M, Bonifacio E, Schmid S et al.
Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents.
Ann Intern Med.
2004;
140
882-886
-
8
Walter M, Albert E, Conrad M et al.
IDDM2 / insulin VNTR modifies risk conferred by IDDM1 / HLA for development of Type 1 diabetes and associated autoimmunity.
Diabetologia.
2003;
46
712-720
-
9
Achenbach P, Koczwara K, Knopff A et al.
Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.
J Clin Invest.
2004;
114
589-597
-
10
Barrett J C, Clayton D G, Concannon P et al.
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.
Nat Genet.
2009;
41
792-798
-
11
Ziegler A G, Schmid S, Huber D et al.
Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies.
JAMA.
2003;
290
1721-1728
-
12
Bonifacio E, Hummel M, Walter M et al.
IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes.
Diabetes Care.
2004;
27
2695-2700
-
13
Achenbach P, Lampasona V, Landherr U et al.
Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk.
Diabetologia.
2009;
52
1881-1888
-
14
Krischer J P, Cuthbertson D D, Yu L et al.
Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes.
J Clin Endocrinol Metab.
2003;
88
103-108
-
15
Achenbach P, Warncke K, Reiter J et al.
Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.
Diabetes.
2004;
53
384-392
-
16
Schlosser M, Strebelow M, Wassmuth R et al.
The Karlsburg type 1 diabetes risk study of a normal schoolchild population: association of beta-cell autoantibodies and human leukocyte antigen-DQB1 alleles in antibody-positive individuals.
J Clin Endocrinol Metab.
2002;
87
2254-2261
-
17
Achenbach P, Bonifacio E, Williams A J et al.
Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives.
Diabetologia.
2008;
51
488-492
-
18
Wenzlau J M, Juhl K, Yu L et al.
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.
Proc Natl Acad Sci USA.
2007;
104
17040-17045
-
19
Wenzlau J M, Liu Y, Yu L et al.
A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes.
Diabetes.
2008;
57
2693-2697
-
20
Sladek R, Rocheleau G, Rung J et al.
A genome-wide association study identifies novel risk loci for type 2 diabetes.
Nature.
2007;
445
881-885
-
21
Keymeulen B, Walter M, Mathieu C et al.
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
Diabetologia.
2010;
53
614-623
-
22
Pescovitz M D, Greenbaum C J, Krause-Steinrauf H et al.
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
N Engl J Med.
2009;
361
2143-2152
-
23
Ludvigsson J, Faresjö M, Hjorth M et al.
GAD treatment and insulin secretion in recent-onset type 1 diabetes.
N Engl J Med.
2008;
359
1909-1920
-
24
Skyler J S, Krischer J P, Wolfsdorf J et al.
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial – Type 1.
Diabetes Care.
2005;
28
1068-1076
-
25
Achenbach P, Barker J M, Bonifacio E.
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.
Curr Diab Rep.
2008;
8
87-93
Prof. Dr. med. A.-G. Ziegler
Institut für Diabetesforschung · Helmholtz Zentrum München
Ingolstädter Landstraße 1
85764 Neuherberg
Email: anette-g.ziegler@helmholtz-muenchen.de
